Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Medicon, Mucodyne among Drugs Subject to MHLW’s Ramp-Up Request
Shionogi’s Medicon (dextromethorphan) and Kyorin Pharmaceutical’s Mucodyne (carbocysteine) are on the list of drugs covered by the health ministry’s recent supply boost request, an emergency step aimed to counter the growing shortage of antitussives and expectorants, the companies told Jiho.…
To read the full story
Related Article
- Shionogi CEO Requests Higher Price for Medicon
November 22, 2024
- 14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
April 15, 2024
- Shionogi Sees 60% Ramp-Up in Medicon Output in FY2023
February 2, 2024
- Shionogi Ships 1st Batch of Cough Drug Medicon after Ramp-Up
December 15, 2023
- 1.4 Billion Yen Booked as Emergency Subsidy for Drug Production Ramp-Up: FY2023 Extra Budget
November 13, 2023
- Health Minister Asks 24 Makers to Raise Production of Antitussives, Expectorants; Firms Want Regulatory, Pricing Steps
November 8, 2023
- Govt to Support Shift to 24-Hour Production for Cough Drugs: Minister
November 8, 2023
- Health Minister to Make Direct Request to 24 Makers for Supply Ramp-Up
November 7, 2023
- Health Minister Requests 8 Makers to Bolster Supplies of Antitussive, Expectorant Agents
October 19, 2023
- JMA Survey Finds Large Gap between Actual Drug Shortage, Industry Poll
October 11, 2023
BUSINESS
- Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
- Samsca Generics Extend Label to ADPKD
April 21, 2026
- ASKA Ups Stake in MedChoice Parent to Deepen Philippines Tie-Up
April 21, 2026
- Nxera Bags US$10 Million Milestone from AbbVie in Neuro Collaboration
April 21, 2026
- Asahi Kasei Closes Aicuris Buy, Eyes US$500 Million Sales by 2030
April 21, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…